tickrz reports
tickrz rank
B
Gilead Sciences Inc (GILD)
Healthcare | Drugs
82.99  0.74%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankB / 137Warren Buffett RankA / 66
Pure Value RankB / 151Dividend RankN/A
Moat RankA / 63Financial Strength RankB / 142
Growth RankA / 3Momentum RankD / 399
GILD vs DRUGS SECTOR & S&P 500
VALUATION
GILDSECTORS&P 500
P/E RATIO8.8835.719.28
EV/EBITDA RATIO5.4325.111.77
P/S RATIO3.817.12.03
P/B RATIO4.788.73.09
QUALITY
RETURN ON EQUITY62.19%16.98%13.82%
RETURN ON CAPITAL95.34%26.23%10.04%
NET MARGIN44.53%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.4%
PAYOUT RATIO22.14%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
4 OUT OF 9
DEBT-TO-EQUITY114%
INTEREST COVERAGE19.08x
CURRENT RATIO3.37
GROWTH
5 YR EPS GROWTH41.14%
5 YR SPS GROWTH29.07%
5 YR BPS GROWTH26.37%
About tickrz
Key Concepts
Great Investors
Gilead Sciences Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank B / 137
Gilead Sciences Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking B / 151Warren Buffett ranking A / 66
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Gilead Sciences Inc's valuation score is comprised of a P/E ratio of 8.9x, a P/B ratio of 4.8x, a P/S ratio of 3.8x, and an EV/EBITDA ratio of 5.4x. Gilead Sciences Inc ranks 151 out of the S&P 500 constituents on valuation--a relatively average score.Gilead Sciences Inc ranks 66 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Gilead Sciences Inc warrants further investigation.

quality
moat A / 63financial strength B / 142
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Gilead Sciences Inc appears to have a durable competitive advantage within the Healthcare sector. Gilead Sciences Inc has a Piotroski F Score of 4 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 19.08x, a debt/equity ratio of 114% and a Moat Rank of 63 translate to an average Financial Strength score.


momentum D / 399
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -7.26% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 399. Based on its 12 month stock performance, Gilead Sciences Inc will not appeal to momentum investors.

yield N/A
value + yield
Unfortunately we do not have enough data to provide a dividend ranking for Gilead Sciences Inc.

growth A / 3
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 41.1% 5 year annualized EPS growth, 29.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 26.4% speak to its impressive growth ranking.

Gilead Sciences Inc (GILD)
Healthcare | Drugs
82.99  0.74%


tickrz rank
B
VALUATION RATIOS
P/E Ratio8.88x
P/B Ratio4.78x
P/S Ratio3.81x
EV/EBITDA Ratio5.43x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.4%
PAYOUT RATIO22.14%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
4 OUT OF 9
DEBT-TO-EQUITY114%
INTEREST COVERAGE19.08x
CURRENT RATIO3.37
MOAT
ROE62.19%
ROIC95.34%
Net Margin44.53%
GROWTH
5 YR EPS GROWTH41.14%
5 YR SPS GROWTH29.07%
5 YR BPS GROWTH26.37%

TICKRZ RANK
Gilead Sciences Inc receives a B ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Gilead Sciences Inc's valuation score is comprised of a P/E ratio of 8.9x, a P/B ratio of 4.8x, a P/S ratio of 3.8x, and an EV/EBITDA ratio of 5.4x. Gilead Sciences Inc ranks 151 out of the S&P 500 constituents on valuation--a relatively average score.

WARREN BUFFETT RANKING
Gilead Sciences Inc ranks 66 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Gilead Sciences Inc warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Gilead Sciences Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Gilead Sciences Inc has a Piotroski F Score of 4 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 19.08x, a debt/equity ratio of 114% and a Moat Rank of 63 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -7.26% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 399. Based on its 12 month stock performance, Gilead Sciences Inc will not appeal to momentum investors.

VALUE + YIELD
Unfortunately we do not have enough data to provide a dividend ranking for Gilead Sciences Inc.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 41.1% 5 year annualized EPS growth, 29.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 26.4% speak to its impressive growth ranking.